Inclusion Criteria:

          1. Men and women, ≥ 18 years of age

          2. Willing and able to give written informed consent

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days
             prior to registration

          4. Radiation Therapy Oncology Group (RTOG) neurological function score of 0-1 within 28
             days prior to registration

          5. Histologic diagnosis of NSCLC, SCLC, Melanoma OR ccRCC

          6. Stage IV cancer with brain metastases (Patients may have untreated primary disease)

          7. Presenting with previously un-irradiated brain metastasis (10 cc maximum volume of
             brain disease based on the diagnostic screening MRI done within 28 days of
             registration))

          8. Measurable/evaluable brain disease

          9. Having received less than 4 lines of prior systemic treatments

         10. Ability to be treated with either gamma knife or a linear accelerator based
             radiosurgery system

         11. Ability to complete neurocognitive exams without assistance

         12. Ability to complete QOL questionnaires with or without assistance

         13. Screening laboratory values must meet the following criteria and should be obtained
             within 28 days prior to registration:

               -  White Blood Cell (WBC) ≥ 2000/uL

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

               -  Platelets≥ 100 x 109/L

               -  Hemoglobin ≥ 90 g/L (may be transfused)

               -  Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance ≥ 50
                  ml/min (calculated -cockcroft-Gault)

               -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤3 x ULN without
                  liver metastasis,≤ 5 x ULN with liver metastases

               -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have
                  total bilirubin < 3.0 mg/dL)

         14. Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (28
             days plus the time required for Nivolumab to undergo five half-lives) after the last
             dose of investigational drug

         15. Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
             start of Nivolumab

         16. Women must not be breastfeeding

         17. Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year. Men receiving Nivolumab and who are sexually
             active with WOCBP will be instructed to adhere to contraception for a period of 31
             weeks after the last dose of Nivolumab product. Women who are not of childbearing
             potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men
             do not require contraception).

        Exclusion Criteria:

          1. Brain metastasis in the brainstem

          2. Patients who experienced prior seizures are eligible, however patients should not have
             had a seizure within 7 days of registration without the use of corticosteroids.

          3. All other cancer histology other than NSCLC or ccRCC

          4. Patients who cannot undergo MRI

          5. Active, known or suspected autoimmune disease. Subjects are permitted to enroll if
             they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to
             autoimmune condition only requiring hormone replacement, psoriasis not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger

          6. Patients with a condition requiring systemic treatment with either corticosteroids
             including steroids used for treating peritumoral edema (> 50 mg daily prednisone
             equivalents) or other immunosuppressive medications within 14 days of study drug
             administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg
             daily prednisone equivalents are permitted in the absence of active autoimmune
             disease.

          7. Drugs with a predisposition to hepatoxicity should be used with caution in patients
             treated with Nivolumab-containing regimen

          8. Any underlying medical or psychiatric condition, which in the opinion of the
             investigator will make the administration of Nivolumab hazardous or obscure the
             interpretation of AEs, such as a condition associated with frequent diarrhea.

          9. History of prior treatment with a CTLA-4, PD-1 or PD-L1 inhibitor, CD137 agonist, or
             anti-PD-L2.

         10. Concomitant therapy with any of the following: IL-2, interferon, or other non-study
             immunotherapy regimens; immunosuppressive agents; other investigation therapies

         11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (eg, infectious) illness.

         12. Known history of hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
             ribonucleic acid (HCV antibody) indicating acute or chronic infection

         13. History of allergy to study drug components.

         14. Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS).